Rosen Michael R, Robinson Richard B, Brink Peter, Cohen Ira S
Center for Molecular Therapeutics, Department of Pharmacology, Columbia University, 630 West 168 Street, PH 7 West-321, New York, NY 10032, USA.
Anat Rec A Discov Mol Cell Evol Biol. 2004 Oct;280(2):1046-52. doi: 10.1002/ar.a.20073.
In recent years, several groups have reported a variety of strategies for developing biological pacemakers whose ultimate function would be to supplement/replace electronic pacemakers. Strategies have included gene therapy using naked plasmids or viral vectors and cell therapy for which both adult human mesenchymal stem cells (hMSCs) and human embryonic stem cells have been employed. This article reviews the various approaches and summarizes our own research in which the pacemaker gene, HCN2, is administered via viral vector or in an hMSC platform to produce pacemaker function in the intact canine heart.
近年来,多个研究小组报道了多种开发生物起搏器的策略,其最终功能是补充/替代电子起搏器。这些策略包括使用裸质粒或病毒载体的基因治疗以及细胞治疗,其中已采用成人骨髓间充质干细胞(hMSC)和人类胚胎干细胞。本文综述了各种方法,并总结了我们自己的研究,即在完整犬心脏中通过病毒载体或hMSC平台给予起搏器基因HCN2以产生起搏器功能。